Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 13/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | CHKA | P35790 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045720 | 1.00 | ADCY5 (1.00) | ADCY5ADORA2ACHKACYP1A2CYP3A4 | |
| SCHEMBL979020 | 1.00 | ADCY5 (1.00) | ADCY5ADORA2ACHKACYP1A2CYP3A4 | |
| SCHEMBL14956936 | 1.00 | ADCY5 (1.00) | ADCY5ADORA2ACHKACYP1A2CYP3A4 | |
| SCHEMBL6045721 | 1.00 | ADCY5 (1.00) | ADCY5ADORA2ACHKACYP1A2CYP3A4 | |
| SCHEMBL6045679 | 1.00 | ADCY5 (1.00) | ADCY5ADORA2ACHKACYP1A2CYP3A4 | |
| SCHEMBL6045706 | 0.86 | ADCY5 (0.76) | ADCY5ADORA2ACHKACYP1A2CYP3A4 | |
| SCHEMBL6045812 | 0.86 | ADCY5 (0.76) | ADCY5ADORA2ACHKACYP1A2CYP3A4 | |
| SCHEMBL19714899 | 0.85 | ADCY5 (0.73) | ADCY5ADORA2ACHKACYP1A2CYP3A4 | |
| SCHEMBL19714823 | 0.85 | ADCY5 (0.73) | ADCY5CHKA | |
| SCHEMBL19714847 | 0.84 | ADCY5 (0.72) | ADCY5CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | ADCY5, ADCY6, ADCY2 | ADCY5 1/4885ADORA2A 303/4885CHKA 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.